A medical journal article published by the Journal of the American College of Cardiology in October 2018 reports that Imbruvica cardiovascular adverse drug reactions often occurred soon after the administration of Imbruvica.
In summary, patients treated with Imbruvica had an increased occurrence of severe and sometimes fatal cardiac events, with Imbruvica cardiovascular toxicities suspected in these higher serious side effects rates, according to a recent clinical trial where Imbruvica therapy was compared with conventional chemotherapy.
Imbruvica received initial FDA approval in 2013. There were several changes made to the Warnings and Precautions section of the Prescribing Information for Imbruvica in July 2019, some of which addressed Imbruvica cardiovascular toxicities discussed in this recent medical study article.
We will continue to monitor the drug safety profile of Imbruvica and watch for any additional Imbruvica drug label changes.[View article at original source]